Funding for this research was provided by:
Ferring Pharmaceuticals
Ocelot Bio, Inc.
Article History
Accepted: 6 August 2023
First Online: 22 August 2023
Declarations
:
: This work was supported by Ferring Pharmaceuticals A/S and publication of the data was supported by Ocelot Bio., Inc.
: Stan Bukofzer and Geoff Harris are founders of Ocelot Bio, Inc; Stan Bukofzer, Geoff Harris, and William R. Ravis are consultants/advisors to Ocelot Bio, Inc. Yu Bagger was an employee of Ferring Pharmaceuticals A/S at the time of the study.
: Data archiving is not mandated, but data will be made available upon a reasonable request to the corresponding author.
: This study was conducted at one site in the USA (New Orleans Center for Clinical Research, Knoxville, TN) between September 2014 and March 2015. The protocol and informed consent forms for this study were reviewed by the institutional review board (Crescent City IRB, New Orleans, LA) and conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements.
: All participants gave their written informed consent before any study-related procedures.
: Not applicable.
: Not applicable.
: Conceptualization: GH; Methodology: GH; Formal analysis: WRR and GH; Investigation: YB; Data curation: YB and GH; Writing—original draft preparation: SB; Writing—review and editing: All authors; Funding acquisition: SB; Supervision: GH and SB; Project administration: SB.